Introduction:
Renal transplantation is the most effective treatment for patients with end stage renal disease (ESRD) offering improved quality of life. Despite advances in immunosuppressive therapies, rejection of the transplanted kidney remains a significant challenge. Antibody-mediated rejection is one of the leading cause of graft dysfunction and graft loss after kidney transplant. The identification of anti HLA (human leucocyte antigen) antibodies including donor specific antibodies (DSAs) and non DSAs are part of standard of care in patients undergoing kidney transplant.
Methods:
This is a prospective observational study is being conducted at Department of Nephrology and Department of genetics at Sir Ganga Ram Hospital, New Delhi started from Aug, 2023 and is ongoing. In this study we have included the patients who are undergoing living donor transplantation are included. Single antigen bead assay for detection HLA antibodies was done by department of HLA genetics. And patients were observed In the post-transplant period and early graft dysfunction was assessed clinically by urine output per day and by laboratory measurement of serum creatinine during first 3 months of transplantation.
Results:
Interim results of the study. 53 patients were included in the study, in which 46 were male and 7 were female. Single antigen bead class 1 was positive in 31 patients and class 2 was positive in 22 reports. 4 patients had DSA (donor specific antibodies) for which appropriate desensitization was followed. In post-transplant period, it was observed that 6 patients had graft dysfunction, two had ABMR.
Conclusions:
This study provides valuable insights into the transplant immunological work up, and utility of single antigen bead assay In Indian population.
I have no potential conflict of interest to disclose.
I did not use generative AI and AI-assisted technologies in the writing process.